Sign in Subscribe
Scientists

Decoding the Complexity of Cancer: New Insights into Acute Myeloid Leukemia and Brain Tumors

Strategic Insights

— 1 min read

Researchers at Washington University School of Medicine in St. Louis have made significant progress in understanding the genetic makeup of cancer patients, particularly those with acute myeloid leukemia (AML) and brain tumors. By sequencing the complete DNA of a patient with AML, the team has identified a suite of genetic changes in the cancer cells, including mutations that were previously unknown to be linked to leukemia. These findings highlight the potential of cancer genome sequencing to unravel the genetic basis of cancer and could lead to more effective diagnosis, classification, and treatment of patients.

Key Takeaways:

  • The researchers sequenced the genome of a 38-year-old patient with AML, identifying about 750 mutations in the patient's cancer genome, with 64 of them considered likely to be important for the patient's cancer.
  • Twelve of the identified mutations were found in genes that code for proteins, including a mutation in the IDH1 gene linked to gliomas, while 52 mutations were in non-coding regions of the genome that may affect gene expression.
  • The IDH1 mutation was found in 15 samples of AML patients, making it one of the most common mutations linked to AML, and another mutation occurred in one other patient with AML.
  • The researchers are now sequencing additional genomes of patients with AML and have expanded the approach to breast, lung, and ovarian cancers, as well as glioblastomas.
  • The study demonstrates the potential of cancer genome sequencing to find unexpected, recurring genetic mutations that are highly likely to be important for cancer development and progression.
  • The investigators also tested 187 additional samples of DNA from AML patients, looking specifically for any of the 64 mutations, and found significant correlations between certain mutations and AML subtypes.

Statistics:

  • The five-year survival rate for adults with AML is about 20 percent.
  • An estimated 13,000 cases of AML will be diagnosed in the United States this year, and some 9,000 will die of the disease.
  • The study took only a few months to complete and cost about $500,000, one-third of the price tag of sequencing the first cancer patient genome less than a year ago.

Sources:

  • Washington University School of Medicine
  • New England Journal of Medicine (Aug. 5, online reporting)
  • Nature (late last year publication)
  • St. Jude Children's Research Hospital
  • The Genome Center, Washington University
  • Clinical Oncology Week via NewsRx.com (2009)

Read more